TapewireFind a company

person · Reporting owner

Jovan-Embiricos Morana

Disclosed activity across 3 companies

Tapewire entity
41364
SEC CIK
0001575745

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Kalaris Therapeutics, Inc.KLRS · Entity 6805DirectorJune 03, 2026June 04, 2026
TCR2 THERAPEUTICS INC.TCRR · Entity 9432710% ownerDecember 18, 2019December 20, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kalaris Therapeutics, Inc.

Report date June 03, 2026 · Filed June 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02Direct9,000 Reported balance After 2026-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000

F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Fund89,217 Reported balance After 2019-12-18 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2019-12-18 · Sale · Disposed 458 · Balance 89,217

F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund191,309 Reported balance After 2019-12-18 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2019-12-18 · Sale · Disposed 2,433 · Balance 191,309

F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund82,575 Reported balance After 2019-12-19 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2019-12-19 · Sale · Disposed 6,642 · Balance 82,575

F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund155,986 Reported balance After 2019-12-19 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2019-12-19 · Sale · Disposed 35,323 · Balance 155,986

F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund713,723 Reported balance After 2019-12-20 transaction · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · 2019-12-20 · Other · Disposed 586,153 · Balance 713,723

F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners.

F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund161,024 Reported balance After 2019-12-20 transaction · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · 2019-12-20 · Other · Disposed 13,847 · Balance 161,024

F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners.

F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund361,665 Reported balance Holding disclosure · report date 2019-12-18 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 361,665

F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund432,319 Reported balance Holding disclosure · report date 2019-12-18 · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · Balance 432,319

F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Fund330,238 Reported balance Holding disclosure · report date 2019-12-18 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 330,238

F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners.

F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners.

F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cullinan Therapeutics, Inc.

Report date August 02, 2022 · Filed August 05, 2022

Jointly reported with F2 Vision SCS

Section 16 reporting ended · disclosed 2022-08-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,255,963 Last balance in matching sequence After 2022-08-04 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2022-08-02 · Sale · Disposed 4,792 · Balance 1,301,081

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Row 2 · 2022-08-03 · Sale · Disposed 19,129 · Balance 1,281,952

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Row 3 · 2022-08-04 · Sale · Disposed 25,989 · Balance 1,255,963

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Globeways Holdings Ltd.1,136,525 Reported balance Holding disclosure · report date 2022-08-02 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 1,136,525

F5: These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy F2 Bioscience I 2017 Ltd.537,392 Reported balance Holding disclosure · report date 2022-08-02 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 537,392

F6: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy F2 MG Ltd.325,333 Reported balance Holding disclosure · report date 2022-08-02 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 325,333

F7: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy F2-TPO Investments, LLC622,175 Reported balance Holding disclosure · report date 2022-08-02 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 622,175

F8: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy F2 Bio TD, LLC71,599 Reported balance Holding disclosure · report date 2022-08-02 · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · Balance 71,599

F9: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy F2 MC, LLC214,798 Reported balance Holding disclosure · report date 2022-08-02 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 214,798

F10: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy F2 GC, LLC104,762 Reported balance Holding disclosure · report date 2022-08-02 · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · Balance 104,762

F11: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Morana Jovan-Embiricos207,803 Reported balance Holding disclosure · report date 2022-08-02 · row 11 Holding and transaction disclosures are not merged.
1 source row

Row 11 · Balance 207,803

F12: These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F6: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F7: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F8: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F9: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F10: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F11: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F12: These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionSeries A Convertible Preferred Stock · Derivative 20,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 14

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,912,345 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionSeries Seed Convertible Preferred Stock · Derivative 8,000,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 13

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,136,525 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 PurchaseCommon Stock 104,762 $21.00 $2,200,002.00
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 12

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 104,762

F9 · ownership.nature: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 PurchaseCommon Stock 95,238 $21.00 $1,999,998.00
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 11

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 622,175

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 214,798 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 10

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 214,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 71,599 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 9

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 71,599

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 143,198 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 8

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 325,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 71,599 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 7

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 526,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 182,135 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 6

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 182,135

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 455,338 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 5

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 455,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 639,295 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 639,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 2,912,345 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,912,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F3 · ownership.nature: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC Cullinan Therapeutics, Inc. CGEM · Entity 4766 ConversionCommon Stock 1,136,525 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-002048 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

F2 Vision SCS · CIK 0001838409 · 10% owner

F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 Bio TD, LLC · CIK 0001838330 · 10% owner

F2 MC, LLC · CIK 0001838426 · 10% owner

F2 GC, LLC · CIK 0001840637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,136,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.

F2 · ownership.nature: These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionSeries B Convertible Preferred Stock · Derivative 613,496 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · derivative · entry 11

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 411,685 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F5 · ownership.nature: Shared held by F2 MC, LLC ("F2 MC"). Globeways Holdings II Limited is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionSeries B Convertible Preferred Stock · Derivative 2,085,889 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · derivative · entry 10

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,399,732 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F4 · ownership.nature: Shares held by F2 MG Limited ("F2 MG"). Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionSeries B Convertible Preferred Stock · Derivative 368,098 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · derivative · entry 9

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 247,011 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F3 · ownership.nature: Shares held by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionSeries A-2 Convertible Preferred Stock · Derivative 20,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · derivative · entry 8

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 13,420,970 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 PurchaseCommon Stock 2,800,000 $17.00 $47,600,000.00
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · nonDerivative · entry 6

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,800,000

F6 · ownership.nature: Shares held by F2 Capital I 2020 LLC ("F2 2020"). Globeways Holdings II Limited is the appointed manager of F2 2020 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2020. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 PurchaseCommon Stock 100,000 $17.00 $1,700,000.00
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · nonDerivative · entry 5

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 347,011

F3 · ownership.nature: Shares held by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionCommon Stock 411,685 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 411,685

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F5 · ownership.nature: Shared held by F2 MC, LLC ("F2 MC"). Globeways Holdings II Limited is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionCommon Stock 1,399,732 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,399,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F4 · ownership.nature: Shares held by F2 MG Limited ("F2 MG"). Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionCommon Stock 247,011 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 247,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F3 · ownership.nature: Shares held by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 03, 2020 Filed Aug 6, 2020 10:06 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 ConversionCommon Stock 13,420,970 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-021597 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 13,420,970

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2020 Filed Jul 31, 2020 22:44 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantStock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0000899243-20-020932 · doc4.xml · derivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2030-07-29

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) July 29, 2021, and (b) the next annual meeting of the Issuer's stockholders.

Read SEC document
December 20, 2019 Filed Dec 20, 2019 17:31 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 OtherCommon Stock 13,847 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 6

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 161,024

F5 · kind: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners.

F6 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 20, 2019 Filed Dec 20, 2019 17:31 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 OtherCommon Stock 586,153 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 5

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 713,723

F3 · kind: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners.

F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 19, 2019 Filed Dec 20, 2019 17:31 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 35,323 $16.47 $581,819.26
Disclosure

SEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 155,986

F2 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 19, 2019 Filed Dec 20, 2019 17:31 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 6,642 $16.47 $109,403.04
Disclosure

SEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 82,575

F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 18, 2019 Filed Dec 20, 2019 17:31 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 2,433 $17.01 $41,375.60
Disclosure

SEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 191,309

F2 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 18, 2019 Filed Dec 20, 2019 17:31 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 458 $17.01 $7,788.75
Disclosure

SEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 89,217

F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 11, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 4,153 $17.65 $73,310.83
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 12

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 1,299,876

F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 11, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 1,054 $17.65 $18,605.74
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 11

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 330,238

F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 11, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 1,381 $17.65 $24,378.10
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 10

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 432,319

F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 11, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 1,155 $17.65 $20,388.64
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 9

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 361,665

F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 10, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 30,475 $17.62 $537,067.02
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 8

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 1,304,029

F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 10, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 7,741 $17.62 $136,421.19
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 7

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 331,292

F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 10, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 10,135 $17.62 $178,611.13
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 6

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 433,700

F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 10, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 8,479 $17.62 $149,427.11
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 5

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 362,820

F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 09, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 75,067 $17.65 $1,325,015.12
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 1,334,504

F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 09, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 19,070 $17.65 $336,606.48
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 339,033

F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 09, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 24,966 $17.65 $440,677.36
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 443,835

F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
December 09, 2019 Filed Dec 11, 2019 19:09 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 20,886 $17.65 $368,660.87
Disclosure

SEC source: 0000899243-19-028968 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 371,299

F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:36 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 2,085 $15.16 $31,602.55
Disclosure

SEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 1,409,571

F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:36 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 530 $15.16 $8,033.26
Disclosure

SEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 358,103

F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:36 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 693 $15.16 $10,503.87
Disclosure

SEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 392,185

F2 · ownership.nature: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:36 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 580 $15.16 $8,791.12
Disclosure

SEC source: 0000899243-19-025909 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 392,185

F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
September 23, 2019 Filed Sep 24, 2019 20:27 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 5,516 $17.31 $95,489.68
Disclosure

SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 12

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 1,411,656

F6 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
September 23, 2019 Filed Sep 24, 2019 20:27 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 1,401 $17.31 $24,253.27
Disclosure

SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 11

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 358,633

F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
September 23, 2019 Filed Sep 24, 2019 20:27 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 1,835 $17.31 $31,766.42
Disclosure

SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 10

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 469,464

F4 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document
September 23, 2019 Filed Sep 24, 2019 20:27 UTC TCR2 THERAPEUTICS INC. TCRR · Entity 94327 SaleCommon Stock 351 $17.31 $6,076.30
Disclosure

SEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 9

Jovan-Embiricos Morana · CIK 0001575745 · 10% owner

Globeways Holdings Ltd · CIK 0001600769 · 10% owner

Globeways Holdings II Ltd · CIK 0001768161 · 10% owner

F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner

F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner

F2 MG Ltd · CIK 0001767396 · 10% owner

F2 - TPO Investments LLC · CIK 0001767397 · 10% owner

F2 BBG LLC · CIK 0001767415 · 10% owner

F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Fund

Disclosed balance after: 89,675

F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.